EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway

Yang Yi, Joshua Fry, Chaehyun Yum, Rui Wang, Siqi Wu, Sharath Narayan, Qi Liu, Xingxing Zhang, Htoo Zarni Oo, Ning Xie, Yanqiang Li, Xinlei Gao und 13 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci195840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Yang Yi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Prostatic Neoplasms, Adenosine, RNA, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N6-methyladenosine (m 6 A), the most predominant RNA modification in humans, participates in various fundamental and pathological bioprocesses. Dynamic manipulation of m 6 A deposition in the transcriptome is critical for cancer progression, though how this regulation is achieved remains understudied. Here, we report that, in prostate cancer (PCa), Polycomb group (PcG) protein Enhancer of Zeste Homolog 2 (EZH2) exerts an additional function in m 6 A regulation via its enzymatic activity. Mechanistically, EZH2 methylates and stabilizes FOXA1 proteins from degradation, which, in turn, facilitates the transcription of m 6 A reader YTHDF1. Through activating an m 6 A autoregulation pathway, YTHDF1 enhances the translation of METTL14 and WTAP, 2 critical components of the m 6 A methyltransferase complex (MTC), and thereby upregulates the global m 6 A level in PCa cells. We further demonstrate that inhibiting the catalytic activity of EZH2 suppresses the translation process globally through targeting the YTHDF1-m 6 A axis. By disrupting both the expression and interaction of key m 6 A MTC subunits, combinational treatment of EZH2 degrader MS8815 and m 6 A inhibitor STM2457 mitigates prostate tumor growth synergistically. Together, our study decodes a previously hidden interrelationship between EZH2 and mRNA modification, which may be leveraged to advance the EZH2-targeting curative strategies in cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinProstatic NeoplasmsAdenosineRNA, NeoplasmNeoplasm ProteinsMaleHumansRNA-Binding ProteinsMethyltransferasesMethylationAnimalsMiceCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticRNA MethylationRNA Splicing FactorsCell Cycle Proteins

Stichwörter der Autor:innen

Cell biologyOncologyProstate cancer

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanAdenosineRNA-Binding ProteinsN-methyladenosineMethyltransferasesYTHDF1 protein, humanRNA, NeoplasmMETTL14 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Urology and.
  • Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Bioinformatics and Computational Biology Program, University of Minnesota, Minneapolis, Minnesota, USA.
  • Driskill Graduate Program in Life Sciences, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Yi, Y., Fry, J., Yum, C., Wang, R., Wu, S., Narayan, S., Liu, Q., Zhang, X., Oo, H. Z., Xie, N., Li, Y., Gao, X., Yu, X., Hu, X., Li, Q., Keseroglu, K., Özbudak, E. M., Abdulkadir, S. A., Chen, K., …, & Cao, Q. (2026). EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway. Journal of Clinical Investigation. https://doi.org/10.1172/jci195840

Vancouver

Yi Y, Fry J, Yum C, Wang R, Wu S, Narayan S, et al. EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway. Journal of Clinical Investigation. 2026. doi:10.1172/jci195840

BibTeX
@article{Yi2026,
  author = {Yi, Yang and Fry, Joshua and Yum, Chaehyun and Wang, Rui and Wu, Siqi and Narayan, Sharath and Liu, Qi and Zhang, Xingxing and Oo, Htoo Zarni and Xie, Ning and Li, Yanqiang and Gao, Xinlei and Yu, Xufen and Hu, Xiaoping and Li, Qiaqia and Keseroglu, Kemal and Özbudak, Ertuğrul M and Abdulkadir, Sarki A and Chen, Kaifu and Jin, Jian and Zhao, Jonathan C and Dong, Xuesen and Arango, Daniel and Yang, Rendong and Cao, Qi},
  title = {EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci195840}
}
Kostenlos starten →